Loading…
DBVT
DBV Technologies S.A.
NASDAQ· Healthcare· Biotechnology
$13.54-6.04%
Key metrics
- Market cap
- $850.93M
- P/E
- —
- Forward P/E
- —
- P/B
- 5.0x
- Dividend yield
- —
- EPS
- -$3.50
- ROE
- -142.68%
- Profit margin
- 0.00%
- Revenue growth
- -53.30%
- Beta
- -0.24
- 52-week high
- $26.19
- 52-week low
- $8.70
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
- 170
- Châtillon, France
Company description provided by Yahoo Finance.